JDG 2020 Results Presentation
Total Page：16
File Type：pdf, Size：1020Kb
Full Year results Year ended 31 December 2020 David Cicurel, CEO Brad Ormsby, CFO Mark Lavelle, COO 23rd March 2021 About Judges Scientific • Buy and build model within the scientific instrument market • Favourable market – Long term growth drivers – Large pool of potential acquisitions in global niches – Low capital requirements • Track record of acquisitions and reputation as a good acquirer – Nineteen acquisitions since May 2005 • Strict acquisition discipline Long term – Buying sustainable businesses at sensible prices drivers Low capital Shareholder use value Large deal pool 2 The Judges Group Moorfield Fire Testing Technology Quorum Technologies Armfield CoolLED Korvus Sircal KE Technology PE.fibreoptics FIRE Instruments Developments Dia-Stron UHV Design Deben GDS EWB Solutions Instruments THT Oxford Scientifica Aitchee Engineering Cryosystems 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 3 A snapshot of Group customers Universities Industry Other research and compliance OEMs 4 Key Messages Performance Acquisitions Outlook impacted by Heath Scientific (now THT) in COVID-19 May for £7.3m plus excess Uncertainty remains but cash positive signs Order intake, revenues and Korvus Technology in October profits impacted Recovery in order intake still in for £2.6m plus potential £0.4m progress Implemented health and earn-out plus excess cash safety initiatives to enable all Long-term fundamentals of the Earnings-enhancing factories to remain open Group unchanged Demonstrating strength and Localised actions to optimise resilience of strategy 10% increase to final dividend profitability Significantly profitable and cash generative throughout 5 COVID-19 update • Operational – Main priority for the Group has been to protect the safety of our colleagues – Our businesses put in place tailored solutions to allow manufacturing to continue - none of our factories have had to close – Supply chain issues faced at the onset of the pandemic were not serious and were alleviated by some prudent over-purchasing at an early stage – Installations severely curtailed by the international travel restrictions; in spite of efforts to satisfy clients, a number of installations were outstanding at the year-end • Financial – UK furlough scheme facilitated the retention of a number of our colleagues whilst they were unable to work as a result of measures instituted to fight the pandemic. – Directors reduced their own fixed remuneration by an equal average percentage and renounced any increase for 2021 – The £5 million repurposed from our acquisition facility for additional working capital was repaid to Lloyds Bank in December 2020 6 Performance review Highlights Organic revenue Cash from -12.2% 2018FY 2020 operations FY 2020 FY 2019 FY 2019 Total revenue down 3.2% 2017 £14.6m (FY 2019: £19.1m) Organic order intake (2016: £2.7 million) FY 2020 Annual dividend -13.2% FY 2020 FY 2019 Total order book FY 2019 15.8 weeks +10% (2016: £0.7 billion) 55p per share FY 2019 excludes 200p special dividend (2016: £ Adjusted operating Adjusted net profit debt FY2018 2020 - FY2017 2019 FY 2020 17% £5.7m FY 2019 £14.4 million (31 December 2019: (2016: £11.6 million) £2.0m) (2016: £10.5illion) Adjusted EPS Cash balance 2018 FY 20202018 HY 20202017 FY 2019 -20% HY 2019 £15.5m 2017 177.2p (31 December 2019: (2016: 61%) £14.1m) 8 Performance FY 2020 FY 2019 Variance Variance (£m) (£m) (£m) (%) Revenue Operating Revenue 79.9 82.5 (2.6) (3.2)% (£m) costs (£m) 2019 82.5 (65.1) Adjusted operating (65.5) (65.1) 0.4 0.6% Acquisitions 7.5 (6.4) costs Organic revenue - Adjusted operating 14.4 17.4 (3.0) (17.4)% 12.2% down (COVID) (10.1) 4.0 profit Net cost savings 2.0 Interest (0.7) (0.4) 2020 79.9 (65.5) Adjusted PBT 13.7 17.0 (3.2) (19.1)% Effective tax rate 14.8% mainly due Taxation (2.0) (2.5) to R&D tax credits Adjusted PAT 11.7 14.5 (2.8) (19.2)% Adjusting items Adjusting items arising from recent (3.1) (2.6) (post tax) acquisitions - mainly amortisation Statutory PAT 8.6 11.9 (3.2) (27.0)% 9 Order intake 100 Millions 90 • Organic order intake down 13% compared with 2019 80 • Geographically: 70 60 – UK up 8% 50 – Rest of Europe up 3% 40 – North America down 26% 30 – China/HK down 22% – Rest of World down 25% Last 4 months annualised Trailing 12 months Budget • Most of our businesses affected • Organic order book of 14.0 weeks at 31 Dec 2020 (31 Dec 2019: 13.2 weeks) • Total order book 15.8 weeks at 31 Dec 2020 • Good order intake from our more recent acquisitions • First 10 weeks organic order intake slightly ahead of prior year 10 Revenue summary • Organic revenue growth across: Origin of orders and revenue by geography – China/Hong Kong by 18% 2020 2019 • Organic revenue decline in: Orders – North America by 32%. – UK by 6% – Rest of Europe by 3% – Rest of the World by 18% Revenue 85+% of revenues exported 11 Profit bridge £000s 20,000 15,000 10,000 5,000 0 2019 contribution* Organic growth Organic decline Acquisitions 2020 contribution* 12 *Contribution is EBIT from trading subsidiaries before central costs Balance sheet and cash flow Cashflow 2020 (£m) 2019 (£m) Dec 20 Dec 19 Balance Sheet Adjusted EBITDA 16.2 19.1 (£m) (£m) Working capital movements (0.8) 0.5 Cash 15.5 14.1 DB pension contributions (0.2) (0.2) Debt (21.2) (16.1) Exceptional transaction costs (0.6) (0.3) Adjusted net (debt)/cash (5.7) (2.0) Cash generated from ops 14.6 19.1 Minority debt - (0.2) Tax (2.4) (2.2) Working Capital 9.6 6.9 Interest paid (exc. IFRS R-o-U) (0.5) (0.3) DB Pension (net of tax) (2.7) (1.7) IFRS 16 lease repayment (1.1) (0.9) Other assets / liabilities 31.5 25.7 Capex (non-acquisition) (1.3) (1.3) Net assets 33.1 28.7 Capex (acquisition related) (12.5) (0.6) Low net debt despite acquisition outlays Repayment of borrowings (2.9) (2.9) throughout 2020 Drawdown for acquisition 9.8 2.3 Working capital above 10% of annual revenue due to WC buffer drawdown 5.0 - COVID – normally less than 10% WC buffer repayment (5.0) - Dividends (annual) (3.3) (2.7) Armfield DB pension liability increase due to reduced discount rate Dividends (special) - (12.4) Issue of shares 1.0 0.3 Cash conversion 102% – recovery from H1 13 Movement in cash 1.4 (1.6) Return On Total Invested Capital Return on Total Invested Capital ROTIC (Trailing 12 months)* FTT acquisition GDS March 2012 50% Scientifica 40% June 2013 THT May 2020 30% 20% Armfield January 2015 10% 0% *excludes central costs and properties 14 Diversification Group revenue Group revenue by geography FTT Sircal PFO GDS Armfield Dia-Stron Quorum UHV EWB Scientifica CoolLED Deben Oxford UK Rest of Europe Moorfield North America THT China/Hong Kong Korvus Rest of World 15 12½ Year Financial History Financial history Revenue and profit 200 EPS and Dividends 250 20000 100,000 (Excluding special dividends) 80,000 200 15000 150 60,000 150 10000 100 40,000 100 5000 50 20,000 50 0 - 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 0 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Revenue H1 Revenue H2 Adjusted Earnings per Share H1 Adjusted Earnings per Share H2 Operating Profit H1 Operating Profit total FY dividend per share Cash generation Includes special dividend Focus on cash generation COAGR 7.1% for past 12 full years 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 16 FY cash generation Dividend Growth strategy Growth drivers • M&A – Many global niches – Over 2,000 privately held businesses in the UK • Organic growth through – Long term secular organic growth trends in science • Global higher education • Process optimisation – Research and Development • 5-6% of annual revenue – Business optimisation • Leadership programme 18 Acquisitions Acquisition criteria • Strict acquisition discipline • Acquisition attributes: – Strong exporters in their global niche markets; solid EBIT margins – Generate sustainable profits and cashflows – Pay 3 to 6 times EBIT according to size – Borrow up to 2.5 times EBITDA @ 2 to 4% Long deal Crystallisation Financial Honourable in incubation notoriously certainty for process period erratic seller 20 Acquisition of Heath Scientific (THT) • World leading maker of calorimetry instruments - measuring the thermal properties of chemical reactions, particularly lithium batteries • Acquired in May 2020 • £1.3m adjusted operating profit in year to 30 April 2020 • Consideration of £7.3m cash (included £2.0m earn-out) plus excess cash • Financed from the Group's £35 million acquisition facility from Lloyds Bank • Immediately earnings-enhancing 21 Acquisition of Korvus Technology • Design and manufacture of vapour deposition systems used to coat materials with thin films - used for academic and industrial research • Acquired in October 2020 • Revenues of £1.42m and pre-tax profits of £0.74m in year to 31 March 2020 • Initial consideration of £2.64m cash plus a potential £0.4m earn-out plus excess cash • Financed from the Group's £35m acquisition facility from Lloyds Bank • Immediately earnings-enhancing 22 Further investments • Purchased remaining shares in PFO for £1.1m in March 2020 Post balance sheet: • Increased interest in majority owned subsidiary Bordeaux Acquisition Limited from 75.5% to 88% in February 2021 • Consideration was £1.8m (based on an EV of £12.9m plus excess cash) • In 2020, Bordeaux generated £2.8m EBIT Judges initial stake in Bordeaux Judges increased its stake in Judges increased its stake in of 51% (Deben UK vendors 49%) Bordeaux to 75.5% Bordeaux to 88% 2011 2017 2021 Judges purchased Deben UK through Bordeaux acquired Oxford Cryosystems Limited Bordeaux, a newly created buy-out vehicle 23 Post acquisition • Financial – Implement robust financial controls – Reduce debt and reinvest in further acquisitions • Operational – Create environment for businesses to continue to thrive – Support and advice for entity management teams – Peer networking and collaboration – Internal benchmarking to encourage optimal performance • Strategic – Succession planning – Leadership programme – Long term focus ….